Logo

ORIC

ORIC Pharmaceuticals, Inc.

ORIC

ORIC Pharmaceuticals, Inc. • NASDAQ
$11.88 ▲ 0.51% (+0.06)
Market Cap $1.16 B
52w High $14.93
52w Low $3.90
Dividend Yield 0%
P/E -6.95
Volume 603.07K
Outstanding Shares 97.39M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $36.671M ▼ $-32.587M ▲ 0% $-0.33 ▲ $-32.299M ▲
Q2-2025 $0 $39.064M ▲ $-36.355M ▼ 0% $-0.47 ▼ $-38.754M ▼
Q1-2025 $0 $32.718M ▼ $-30.021M ▲ 0% $-0.42 ▲ $-32.416M ▲
Q4-2024 $0 $39.266M ▲ $-36.307M ▼ 0% $-0.51 ▼ $-36.003M ▲
Q3-2024 $0 $38.318M $-34.566M 0% $-0.49 $-38.048M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $287.14M ▲ $431.192M ▲ $24.273M ▲ $406.919M ▲
Q2-2025 $282.513M ▲ $346.857M ▲ $22.862M ▼ $323.995M ▲
Q1-2025 $203.723M ▼ $242.858M ▼ $23.12M ▼ $219.738M ▼
Q4-2024 $255.96M ▼ $274.142M ▼ $31.02M ▲ $243.122M ▼
Q3-2024 $272.369M $302.07M $28.076M $273.994M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-32.587M ▲ $-25.112M ▲ $-110.535M ▼ $109.451M ▼ $-26.196M ▼ $-25.147M ▲
Q2-2025 $-36.355M ▼ $-30.842M ▲ $-76.93M ▼ $134.302M ▲ $26.53M ▲ $-30.905M ▲
Q1-2025 $-30.021M ▲ $-32.775M ▼ $22.45M ▼ $253K ▼ $-10.072M ▼ $-33.162M ▼
Q4-2024 $-36.307M ▼ $-28.054M ▲ $42.655M ▲ $575K ▲ $15.176M ▲ $-28.273M ▲
Q3-2024 $-34.566M $-28.797M $23.07M $126K $-5.601M $-29.215M

Five-Year Company Overview

Income Statement

Income Statement ORIC is still a pure research company with no product sales yet, so all activity runs through its operating expenses. The income statement shows steady, intentional spending on R&D and related costs, leading to recurring annual losses as the company advances its pipeline. Losses have been fairly consistent over the past several years, with a slight trend toward improvement as the company manages expenses. Overall, this is a classic clinical‑stage biotech profile: no revenue, ongoing R&D-driven losses, and results heavily tied to trial progress rather than current commercial performance.

Balance Sheet

Balance Sheet The balance sheet looks typical for a development‑stage biotech: most of the value sits in cash and other assets funded largely by shareholder equity, with very little debt. Cash levels have moved around over the years as the company raises funds and then spends them on R&D. Equity remains the main source of financing, which reduces financing risk from lenders but means the business is dependent on capital markets and/or partnerships to continue funding its programs over time. Asset levels appear stable enough to support current development plans, but the long-term picture still hinges on future funding and trial outcomes.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, reflecting the cost of running clinical programs, paying staff, and supporting the pipeline, all without offsetting product revenue. There is essentially no spending on heavy equipment or facilities, so free cash flow closely mirrors operating cash outflow. This pattern is normal for an early-stage biotech, but it also means the company will need periodic infusions of new capital unless it secures partnership funding or reaches a point of meaningful revenue. The key question is how long the current cash position can support the existing trial plans before additional funding is required.

Competitive Edge

Competitive Edge ORIC is trying to stand out in a crowded oncology field by focusing narrowly on one of the toughest problems in cancer care: resistance to existing treatments. Its niche is to develop medicines that can be combined with or sequenced after other therapies to keep them working longer. This is an important and scientifically complex area, which creates both opportunity and barriers to entry. Larger pharma players are active in oncology, but ORIC’s differentiation comes from its specialized focus on resistance mechanisms, its expertise in hormone‑driven cancers and precision oncology, and its targeted small‑molecule designs. Still, as a smaller clinical‑stage company, it faces the usual challenges: competition from much larger firms, dependence on a limited number of key programs, and heavy reliance on positive clinical data to confirm its edge.

Innovation and R&D

Innovation and R&D Innovation is the core of ORIC’s story. The company is building a pipeline specifically around different forms of cancer resistance—innate, acquired, and bypass mechanisms—rather than pursuing broad, undifferentiated oncology targets. Its lead programs include a drug aimed at a novel resistance-related pathway in advanced prostate cancer and another designed to treat certain lung cancers while also controlling or preventing brain metastases by crossing the blood‑brain barrier. Additional early‑stage candidates, such as inhibitors targeting CD73 and PLK4, deepen the pipeline and diversify scientific bets. Overall, R&D is focused, mechanistically driven, and clearly aligned with a single theme: making existing and future cancer treatments work better and longer. The flip side is high scientific and clinical risk, with significant value resting on a few key trials and milestones.

Summary

ORIC is a classic clinical‑stage biotech: no current revenue, steady R&D‑driven losses, and a balance sheet anchored by cash and equity funding. The company’s appeal rests almost entirely on its scientific strategy and pipeline rather than on current financial performance. Strategically, ORIC is positioned in a high‑value niche—overcoming cancer treatment resistance—with several differentiated drug candidates aiming at important unmet needs in prostate and lung cancer, plus earlier projects to broaden the portfolio. Financially, it has managed its resources with a focus on funding core programs, but ongoing negative cash flow means future progress will depend on continued access to capital and, ideally, partnerships. Overall, ORIC offers a focused, innovation-heavy story with meaningful upside potential if trials succeed, but it also carries the typical binary risks of early-stage oncology development, where a few clinical outcomes can dramatically reshape the company’s prospects.

NEWS

November 24, 2025 · 4:05 PM UTC

ORIC® Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Read more

November 13, 2025 · 4:10 PM UTC

ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

Read more

November 13, 2025 · 4:05 PM UTC

ORIC® Pharmaceuticals Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

Read more

November 7, 2025 · 4:30 PM UTC

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Read more

November 6, 2025 · 4:00 PM UTC

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

Read more